Search research articles
Contact Us
Filters
Showing results (51-60 of 59) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 59 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 17, 2001
Phase II study of sequential administration of docetaxel followed by doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer
D Khayat, P Chollet, E C Antoine, et al.
British Journal of Haematology
|
September 1, 1996
Hepatitis C virus and non-Hodgkin's lymphomas
C Mazzaro, V Zagonel, S Monfardini, et al.
Gynecologic Oncology
|
December 14, 2012
A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14)
F Cognetti, A Bagnato, N Colombo, et al.
Tumori
|
December 23, 1998
Interleukin-2, interferon-alpha and interleukin-2 plus interferon-alpha in renal cell carcinoma. A randomized phase II trial
F Boccardo, A Rubagotti, L Canobbio, et al.
Oncology
|
November 29, 2008
Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial
S Pignata, G Scambia, A Savarese, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 1, 1996
EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group
L Y Dirix, F Tonnesen, J Cassidy, et al.
British Journal of Cancer
|
July 14, 2011
Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer
C K Lee, H Gurney, C Brown, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 19, 2015
Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial
D Lorusso, G Scambia, S Pignata, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 21, 2018
Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer
M C Piccirillo, G Scambia, A Bologna, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 59) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 59 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 17, 2001
Phase II study of sequential administration of docetaxel followed by doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer
D Khayat, P Chollet, E C Antoine, et al.
British Journal of Haematology
|
September 1, 1996
Hepatitis C virus and non-Hodgkin's lymphomas
C Mazzaro, V Zagonel, S Monfardini, et al.
Gynecologic Oncology
|
December 14, 2012
A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14)
F Cognetti, A Bagnato, N Colombo, et al.
Tumori
|
December 23, 1998
Interleukin-2, interferon-alpha and interleukin-2 plus interferon-alpha in renal cell carcinoma. A randomized phase II trial
F Boccardo, A Rubagotti, L Canobbio, et al.
Oncology
|
November 29, 2008
Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial
S Pignata, G Scambia, A Savarese, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 1, 1996
EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group
L Y Dirix, F Tonnesen, J Cassidy, et al.
British Journal of Cancer
|
July 14, 2011
Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer
C K Lee, H Gurney, C Brown, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 19, 2015
Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial
D Lorusso, G Scambia, S Pignata, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 21, 2018
Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer
M C Piccirillo, G Scambia, A Bologna, et al.
Page
of 6